ArticleFrontiers in nutrition2025
Impact of high fasting plasma glucose on liver cancer burden in China: a comprehensive analysis of trends from 1990 to 2021.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High fasting plasma glucose (HFPG), a key metabolic risk factor, has emerged as a major contributor to the global cancer burden, particularly liver cancer. However, little is known about the long-term trends and sex-specific patterns of HFPG-attributable liver cancer in China. Methods: Data were obtained from the Global Burden of Disease Study 2021 to estimate the liver cancer burden attributable to HFPG in China from 1990 to 2021. Metrics analyzed included age-standardized mortality rates (ASMR), disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs). Joinpoint regression and decomposition analyses were conducted to evaluate temporal trends and contributing factors. Results: In 2021, 3,467 deaths and 83,113 DALYs were attributable to HFPG-related liver cancer in China, with males bearing a higher burden than females. Mortality and DALYs peaked in individuals aged 65-69, and age-standardized rates rose with advancing age, especially among men. Between 1990 and 2021, the absolute burden increased, driven by population aging and growth, although age-standardized rates remained relatively stable. Joinpoint regression showed fluctuating trends with recent declines in DALYs and YLLs, especially in females. Compared to global trends, China exhibited more stability in age-standardized rates. Decomposition analysis identified aging as the primary driver of increased deaths, while population growth led the rise in DALYs. Epidemiological changes slightly offset DALYs in women but increased the burden in men. Conclusion: Despite stable age-standardized rates, the absolute burden of HFPG-related liver cancer in China has increased due to demographic shifts, with males and older adults disproportionately affected. Targeted interventions addressing metabolic risk factors in aging populations, particularly men, are urgently needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.